Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

Olive oil antioxidants and non-alcoholic fatty liver disease.

Abenavoli L, Milanović M, Milić N, Luzza F, Giuffrè AM.

Expert Rev Gastroenterol Hepatol. 2019 Jun 19. doi: 10.1080/17474124.2019.1634544. [Epub ahead of print]

PMID:
31215262
2.

Lamium Plants-A Comprehensive Review on Health Benefits and Biological Activities.

Salehi B, Armstrong L, Rescigno A, Yeskaliyeva B, Seitimova G, Beyatli A, Sharmeen J, Mahomoodally MF, Sharopov F, Durazzo A, Lucarini M, Santini A, Abenavoli L, Capasso R, Sharifi-Rad J.

Molecules. 2019 May 17;24(10). pii: E1913. doi: 10.3390/molecules24101913. Review.

3.

Nonalcoholic fatty liver disease in obese adolescents: the role of genetic polymorphisms.

Abenavoli L, Boccuto L.

Hepatobiliary Surg Nutr. 2019 Apr;8(2):179-180. doi: 10.21037/hbsn.2018.12.03. No abstract available.

4.

Non-invasive assessment of liver fibrosis in HCV patients compared to liver biopsy: the experience of tertiary level Hospital in Serbia.

Preveden T, Vereš B, Ružić M, Pete M, Luzza F, Pellicano R, Abenavoli L.

Minerva Med. 2019 May 6. doi: 10.23736/S0026-4806.19.06109-3. [Epub ahead of print]

PMID:
31081313
5.

Older age and HDL-cholesterol as independent predictors of liver fibrosis assessed by BARD score.

Klisic A, Abenavoli L, Fagoonee S, Kavaric N, Kocic G, Ninić A.

Minerva Med. 2019 Jun;110(3):191-198. doi: 10.23736/S0026-4806.19.05978-0. Epub 2019 Feb 14.

PMID:
30784251
6.

Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey.

Larussa T, Rossi M, Suraci E, Marasco R, Imeneo M, Abenavoli L, Luzza F.

Medicina (Kaunas). 2019 Feb 13;55(2). pii: E46. doi: 10.3390/medicina55020046.

7.

Preface.

Abenavoli L.

Rev Recent Clin Trials. 2019;14(1):3. doi: 10.2174/157488711401190110101233.

PMID:
30741130
8.

Neuropathic diabetic foot ulcers treated with cerium dioxide nanoparticles: A case report.

Kobyliak N, Abenavoli L, Kononenko L, Kyriienko D, Spivak M.

Diabetes Metab Syndr. 2019 Jan - Feb;13(1):228-234. doi: 10.1016/j.dsx.2018.08.027. Epub 2018 Aug 29.

PMID:
30641702
9.

Influence of FTO rs9939609 and Mediterranean diet on body composition and weight loss: a randomized clinical trial.

Di Renzo L, Cioccoloni G, Falco S, Abenavoli L, Moia A, Sinibaldi Salimei P, De Lorenzo A.

J Transl Med. 2018 Nov 12;16(1):308. doi: 10.1186/s12967-018-1680-7.

10.

Effect of Chondroitin Sulfate on Blood Serum Cytokine Profile during Carrageenan-induced Edema and Monoiodoacetate-induced Osteoarthritis in Rats.

Korotkyi O, Vovk A, Blokhina O, Dvorshchenko K, Falalyeyeva T, Abenavoli L, Ostapchenko L.

Rev Recent Clin Trials. 2019;14(1):50-55. doi: 10.2174/1574887113666181102111247.

PMID:
30387401
11.

Polycystic ovary syndrome: the potential role of probiotic supplementation.

Abenavoli L, Dumitrascu DL.

Minerva Med. 2019 Feb;110(1):1-2. doi: 10.23736/S0026-4806.18.05889-5. Epub 2018 Oct 29. No abstract available.

12.

Is possible to detect nonalcoholic fatty liver disease by a new index including single nucleotide polymorphisms (SNPs)?

Abenavoli L, Boccuto L.

Ann Transl Med. 2018 Sep;6(18):366. doi: 10.21037/atm.2018.09.20. No abstract available.

13.

Rosmarinic Acid as Potential Anti-Inflammatory Agent.

Colica C, Di Renzo L, Aiello V, De Lorenzo A, Abenavoli L.

Rev Recent Clin Trials. 2018;13(4):240-242. doi: 10.2174/157488711304180911095818.

PMID:
30328397
14.

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.

Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N.

Pharmaceuticals (Basel). 2018 Oct 11;11(4). pii: E104. doi: 10.3390/ph11040104. Review.

15.

Variability in Phelan-McDermid syndrome: The impact of the PNPLA3 p.I148M polymorphism.

Boccuto L, Abenavoli L, Cascio L, Srikanth S, DuPont B, Mitz AR, Rogers RC, Phelan K.

Clin Genet. 2018 Dec;94(6):590-591. doi: 10.1111/cge.13451. Epub 2018 Oct 11.

PMID:
30308089
16.

Correction to: An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD).

Simeoni M, Citraro ML, Cerantonio A, Deodato F, Provenzano M, Cianfrone P, Capria M, Corrado S, Libri E, Comi A, Pujia A, Abenavoli L, Andreucci M, Cocchi M, Montalcini T, Fuiano G.

Eur J Nutr. 2018 Oct 9. doi: 10.1007/s00394-018-1831-x. [Epub ahead of print]

PMID:
30302543
17.

Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study.

Kobyliak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, Kyriienko D, Komisarenko I, Dynnyk O.

Minerva Med. 2018 Dec;109(6):418-428. doi: 10.23736/S0026-4806.18.05845-7. Epub 2018 Sep 13.

PMID:
30221912
18.

Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.

Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R.

Phytother Res. 2018 Nov;32(11):2202-2213. doi: 10.1002/ptr.6171. Epub 2018 Aug 6. Review.

PMID:
30080294
19.

An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD).

Simeoni M, Citraro ML, Cerantonio A, Deodato F, Provenzano M, Cianfrone P, Capria M, Corrado S, Libri E, Comi A, Pujia A, Abenavoli L, Andreucci M, Cocchi M, Montalcini T, Fuiano G.

Eur J Nutr. 2018 Aug 3. doi: 10.1007/s00394-018-1785-z. [Epub ahead of print] Erratum in: Eur J Nutr. 2018 Oct 9;:.

PMID:
30076458
20.

Health benefits of Mediterranean diet in nonalcoholic fatty liver disease.

Abenavoli L, Di Renzo L, Boccuto L, Alwardat N, Gratteri S, De Lorenzo A.

Expert Rev Gastroenterol Hepatol. 2018 Sep;12(9):873-881. doi: 10.1080/17474124.2018.1503947. Epub 2018 Aug 1. Review.

PMID:
30033779

Supplemental Content

Loading ...
Support Center